Evidence map›Paper›PMID 40849783›Full record

ArticleCurrent medical imaging2025

Initial Recurrence Risk Stratification of Papillary Thyroid Cancer based on Intratumoral and Peritumoral Dual Energy CT Radiomics.

Yan Zhou, Yongkang Xu, Yan Si, Feiyun Wu, Xiaoquan Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yan ZhouDepartment of Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Yongkang XuDepartment of Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Yan SiDepartment of Thyroid Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Feiyun WuDepartment of Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Xiaoquan XuDepartment of Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study aims to evaluate the potential of Dual-Energy Computed Tomography (DECT)-based radiomics in preoperative risk stratification for the prediction of initial recurrence in Papillary Thyroid Carcinoma (PTC).

methodsThe retrospective analysis included 236 PTC cases (165 in the training cohort, 71 in the validation cohort) collected between July 2020 and June 2021. Tumor segmentation was carried out in both intratumoral and peritumoral areas (1 mm inner and outer to the tumor boundary). Three regionspecific rad-scores were developed (rad-score [VOI

resultsRad-scores from peritumoral regions (VOI DISCUSSION: DECT-based intratumoral and peritumoral radiomics advance PTC initial recurrence risk prediction, providing clinical radiology with precise predictive tools. Further work is needed to refine the model and enhance its clinical application.

conclusionRadiomics analysis of DECT, particularly in peritumoral regions, offers valuable predictive information for assessing the risk of initial recurrence in PTC.

Indexed as

Neoplasm Recurrence, LocalThyroid Cancer, PapillaryThyroid NeoplasmsTomography, X-Ray ComputedAdultAgedFemaleHumansMaleMiddle AgedNomogramsRadiomicsRetrospective StudiesRisk AssessmentAmerican thyroid association.Dual-energy computed tomographyMachine learningMultidetector computed tomographyPapillary thyroid cancerPrognosisRadiomics

Identifiers

PMID40849783
PMCPMC13223471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.